Clinical trials
Chidamide clinical trials
Below are recruiting chidamide clinical trials, each written for real people, not researchers. We’re tracking 67 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05682755RecruitingPhase 1/Phase 2
Chidamide to Prevent AML Return After Bone Marrow Transplant
This Phase 1/2 study tests whether chidamide can help prevent high-risk acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow transplant (allo-HSCT). Participants must already be in complete remission and have recovered blood counts after transplant.
Chengdu, SichuanAges 18–65 - NCT05958719RecruitingPhase 2
Chidamide plus chemotherapy for new nodal TFH cell lymphoma
This trial studies whether adding chidamide to a combination chemotherapy plan (azacitidine, liposomal mitoxantrone, and prednisone) works better for people newly diagnosed with nodal T-follicular helper (TFH) cell lymphoma. It’s testing a treatment strategy after diagnosis to improve disease control and outcomes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05976997RecruitingPhase 2
Test duvelisib plus chidamide for newly diagnosed PTCL
This trial studies whether the combination of duvelisib and chidamide can treat newly diagnosed peripheral T-cell lymphoma (PTCL). Because it is a single-arm study, everyone gets the treatment, and the team monitors response and safety.
Wuhan, HubeiAges 18–70 - NCT06066905Recruiting
Study of chidamide and azacitidine for AML patients with MRD after transplant
This trial tests whether a combination of two drugs, chidamide and azacitidine (AZA), can help people with acute myeloid leukemia (AML) who still have small amounts of leukemia cells (called MRD) after a stem cell transplant. The goal is to see if this treatment can clear those leftover cells and lower the chance of the leukemia coming back.
Guangzhou, GuangdongAges 18 years+ - NCT06151106RecruitingPhase 2
Study of Chidamide and Duvalisib for Relapsed or Resistant T-Cell Lymphoma
This trial tests a combination of two targeted drugs, Chidamide and Duvalisib, for people with peripheral T-cell lymphoma or NK/T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this drug combination can help shrink or control the lymphoma.
Xiamen, FujianAges 18–75 - NCT06158386RecruitingPhase 2
Chidamide and linperlisib for relapsed follicular lymphoma
This trial tests a combination of two oral drugs, chidamide and linperlisib, for people with follicular lymphoma that has not responded to or come back after at least two prior treatments. The goal is to see if this combination can help shrink the lymphoma and stop it from growing.
Xiamen, FujianAges 18 years+ - NCT06220487RecruitingPhase 2
New drug combo for Ph+ ALL without transplant
This trial tests a combination of three drugs—olverembatinib, a bispecific T-cell engager, and chidamide—for adults newly diagnosed with Ph+ ALL who cannot have a stem cell transplant. The goal is to see if this treatment works well without needing intensive chemotherapy.
Guangzhou, GuangdongAges 18 years+ - NCT06386302Recruiting
Chidamide, venetoclax, and azacitidine for new AML
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06421948RecruitingPhase 1/Phase 2
Linperlisib and chidamide for PTCL
This trial tests two pills—linperlisib and chidamide—for people with a type of lymphoma called PTCL. The combination might work better together than either alone.
Zhengzhou, HenanAges 18–80 - NCT06584227RecruitingPhase 2
Adebrelimab and Chidamide for advanced pancreatic cancer
This trial tests a combination of two drugs (Adebrelimab and Chidamide) in people with advanced pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Nanjing, JiangsuAges 18–75 - NCT06637007RecruitingPhase 2
Chidamide plus AK112 for advanced sarcoma after first treatment
This trial tests two new drugs (chidamide and AK112) together for people with advanced bone or soft tissue sarcoma that has not responded to standard first-line treatment. The goal is to see if this combination can shrink tumors or slow their growth.
Taiyuan, ShanxiAges 18–75 - NCT05833724RecruitingPhase 2
Chidamide for relapsed or resistant peripheral T-cell lymphoma
This trial tests chidamide (a targeted medicine that affects how cells manage gene activity) in people whose peripheral T-cell lymphoma has come back or did not respond to treatment. It may help shrink measurable tumors and control the disease after prior therapies.
Kaohsiung CityAges 20–75 - NCT06776952RecruitingPhase 3
Study of XNW5004 for relapsed or refractory peripheral T-cell lymphoma
This study tests a new oral tablet called XNW5004 for people with peripheral T-cell lymphoma (a type of blood cancer) that has come back or not responded to prior treatments. The goal is to see if this drug can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 3 weeks–2 months - NCT06951997RecruitingPhase 2
First treatment for metastatic pancreatic cancer using three drugs
This trial tests a new combination of three drugs (QL1706, chidamide, and AG) as the very first treatment for people with metastatic pancreatic cancer. The goal is to see if this combination is safe and effective, and it may offer a new option for those who have not had any prior therapy.
TianjinAges 18–75 - NCT06979908RecruitingPhase 2
A study of fruquintinib plus immunotherapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Changchun, JilinAges 18–75 - NCT07093710RecruitingPhase 1/Phase 2
Golidocitinib combo for relapsed peripheral T-cell lymphoma
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
Guangzhou, GuangdongAges 18 years+ - NCT07159620RecruitingPhase 2
New drug combo for rare leukemia type (ETP-ALL)
This trial tests a combination of drugs (venetoclax, azacitidine, chidamide, vindesine, and dexamethasone) in people newly diagnosed with a rare subtype of T-cell acute lymphoblastic leukemia called ETP-ALL or near-ETP-ALL. The goal is to see if this drug cocktail can improve outcomes.
Suzhou, JiangsuAges 14–65 - NCT07318831RecruitingPhase 2
Combination drug therapy for relapsed neuroblastoma
This trial tests a combination of four drugs (chidamide, dinutuximab beta, irinotecan, and temozolomide) for children whose neuroblastoma has returned or isn't responding to standard treatment. It aims to see if this mix can shrink the tumor or stop it from growing.
Tianjin, Tianjin MunicipalityAges Any age - NCT07373964RecruitingPhase 2
Study of new drug combo for extensive-stage small-cell lung cancer
This trial tests a new combination of drugs (chidamide, a PD-L1 inhibitor, carboplatin, and etoposide) as the first treatment for people with extensive-stage small-cell lung cancer. The goal is to see if this combination works better than standard treatments.
Shenyang, LiaoningAges 18–75 - NCT07489989RecruitingPhase 2
Combination therapy to boost CAR-T for B-cell lymphoma
This trial tests a new combination of drugs to make CAR-T cell therapy work better for people with certain types of B-cell lymphoma. It adds the drugs chidamide and a PD-1 inhibitor to the usual CAR-T treatment, aiming to improve response.
Beijing, Beijing MunicipalityAges 18–85 - NCT07493109RecruitingPhase 3
Maintenance treatment for hepatitis B-related lymphoma after initial therapy
This trial tests whether the drug chidamide, taken after initial successful treatment, can help prevent relapse in people with a type of lymphoma (diffuse large B-cell lymphoma) who also have chronic hepatitis B. Participants must have achieved complete remission after six cycles of standard chemotherapy (R-CHOP).
Changchun, JilinAges 18–80 - NCT07507318RecruitingPhase 2
Low-dose chemo to prevent relapse in high-risk DLBCL patients
This trial tests a low-dose chemotherapy pill (chidamide) for people with a certain high-risk type of DLBCL that still has signs of cancer in the blood after initial treatment. The goal is to keep the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07570849RecruitingPhase 2
Chidamide with chemotherapy and immunotherapy for advanced bile duct cancer
This trial tests a combination of three treatments—chidamide (a new type of cancer drug), chemotherapy, and immunotherapy—for advanced intrahepatic cholangiocarcinoma (a cancer of the bile ducts inside the liver). The goal is to see if this combination can shrink tumors and help patients live longer when used as a first treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05690191Enrolling by invitation
Chidamide treatment for returning or hard-to-treat lymphoma
This trial studies chidamide (a prescription medicine) in people with diffuse large B-cell lymphoma that has come back or did not respond to at least one prior treatment. It may help shrink tumors and improve disease control for eligible patients.
Suzhou, JiangsuAges 18 years+
Hear when a new Chidamide trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chidamide?
- Yes. Clin2 currently lists 67 recruiting chidamide studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chidamide trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chidamide trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.